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Despite theextensiveapplicationofmultispectral imaging (MSI) inbiomedicalmultidisciplinary researches, there is apaucity
of data available regarding the implication of MSI in tumor prognosis prediction. We compared the behaviors of
multispectral (MS) and conventional red-green-blue (RGB) images on assessment of human epidermal growth factor
receptor 2 (HER2) immunohistochemistry to explore their impact on outcome in patients with invasive breast cancer (BC).
Tissue microarrays containing 240 BC patients were introduced to compare the performance of MS and RGB imaging
methods on the quantitative assessment of HER2 status and the prognostic value of 5-year disease-free survival (5-DFS).
Both the total and average signal optical density values of HER2MS and RGB images were analyzed, and all patients were
divided into twogroupsbasedon thedifferent 5-DFS. ThequantificationofHER2MS imageswasnegatively correlatedwith
5-DFS in lymph node–negative and –positive patients (P b .05), but RGB images were not in lymph node–positive patients
(P = .101). Multivariate analysis indicated that the hazard ratio (HR) of HER2 MS was higher than that of HER2 RGB
(HR = 2.454; 95% confidence interval [CI], 1.636-3.681 vs HR = 2.060; 95% CI, 1.361-3.119). Additionally, area under
curve (AUC) by receiver operating characteristic analysis for HER2MSwas greater than that for HER2 RGB (AUC = 0.649;
95% CI, 0.577-0.722 vs AUC = 0.596; 95% CI, 0.522-0.670) in predicting the risk for recurrence. More importantly, the
quantification of HER2MS images has higher prediction accuracy than that of HER2 RGB images (69.6% vs 65.0%) on 5-
DFS. Our study suggested that better information on BC prognosis could be obtained from the quantification of HER2MS
images and MS images might perform better in predicting BC prognosis than conventional RGB images.
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Breast cancer (BC) is the most frequently diagnosed cancer and the leading
cause of cancer death among females worldwide [1]. InChina, the incidence
of BC has been on a steady rise despite improvements in screening and
comprehensive treatment [2]. Human epidermal growth factor receptor 2
(HER2), also known as c-erbB-2 or HER2/neu, is a commonly used
theranostic biomarker for BCs, which is overexpressed in approximately
20% to 25% of invasive BCs [3–6]. Currently, the HER2-based
molecular-targeted therapy plays a tremendous impact on BC prognosis
[6–8]. Therefore, accurate quantitative determination of HER2 status is
crucial for the establishment of BC treatment strategy in clinical practice.
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status. One is immunohistochemistry (IHC) for the determination of
HER2 protein expression, and the other is fluorescence in situ
hybridization for the sensing of HER2 gene [9]. The former is
recommended as a primary testing modality, and the latter is
considered in ambiguous cause. However, interpreting IHC images
by manual assessment is highly experience based and subjective.
Additionally, no unified judgment and a lack of reproducibility as
well as the potentially drastic variations among inter- and
intraobservers further limited this technique [10,11]. Therefore, an
accurate and repeatable quantitative method for IHC images becomes
increasingly desirable in clinical histopathology. Computer image
analysis of IHC images possessed the promising potential for more
consistent interpretation and minimized the influence of subjective
human factor compared with manual assessment [10,12]. However,
the image quality would affect the analysis result no matter by
pathologist or computer-aided image analysis [13]. Thus, it is a
prerequisite to obtain high-quality IHC images and the related
accurate quantitative analysis for the assessment of BC prognosis.
The conventional red-green-blue (RGB) imaging has been widely
used, but their inherent technical limitations such as suboptimal
image contrast and sharpness, overlapping chromogenic signals, and
strong light effect affected the accuracy and repeatability of IHC
image quantification and analysis obviously [14,15]. To address this
issue, multispectral imaging (MSI) systems have been introduced and
used for the separation of different cellular components and unmixing
of overlapping chromogens [16,17]. Different from traditional RGB
imaging, MSI can capture high-resolution images with a high degree
of spectral information and facilitate the extraction of specific
chromogen signal from the bright-field image even in the case of
spatial and spectral overlap [17–19]. Moreover, the precise separation
and independent quantitation of multiple markers in the subcellular
compartments can be realized by MSI combined with advanced cell
segmentation software [20].
In our previous study, the utility of MS images in quantitative IHC
analysis showed higher sensitivity and accuracy, and better image
quality and reliability than standard RGB images [15]. Furthermore,
quantum dots–based MSI has been used for the obtainment of
prognostic indicators of multiple proteins or genes in the tumor and
tumor microenvironment [9,21,22]. But little is known concerning
the prognostic value of quantitative assessment of bright-field MS
images in BC patients. Herein, we employed MS and conventional
RGB images for the quantitative analysis of HER2 IHC and
compared the results to evaluate their performance in the prediction
of BC prognosis.
Materials and Methods
Patients and Specimens
Complete tumor specimens from 240 invasive BC patients from
our prospectively established BC database at our cancer center, which
has been the source of our recent clinical studies on BC, were selected
[9,23]. Major demographic and clinicopathologic characteristics were
available, including age, tumor size, lymph node (LN) status,
histological grade, hormone receptor status, and HER2 gene status.
TNM staging and histological grade were classified according to the
seventh edition of the American Joint Committee on Cancer TNM
system [24] and the fourth edition of the WHO histological grade
[25]. Major treatment information including types of surgery andadjuvant treatments (chemo/radiotherapy and endocrine therapy) was
obtained from the medical records of each patient. The
HER2-positive patients did not receive the molecular targeting
therapy. All the patients were on regular follow-up schedule, and the
complete information on 5-year disease-free survival (5-DFS) was
available. Informed consents were obtained from all patients in the
database, and the study was approved by the institutional review
board and the ethics committee.
Tissue Microarray (TMA) Construction
All hematoxylin and eosin–stained slides were examined by
independent reviewers who were blinded from the clinical features
or outcomes. BC TMAs were constructed using standard procedures,
as previously described [26]. Briefly, two cores were taken from each
representative invasive tumor tissue (1.5 mm in diameter for each
core). Then, 7 different TMAs sections with 240 tumor tissues were
constructed (in collaboration with Shanghai Outdo Biotech Co. Ltd.,
Shanghai, China) (Figure 1A1).
Immunohistochemistry and Evaluation
Immunolocalization of HER2, estrogen receptor (ER), and
progesterone receptor (PR) was performed using streptavidin-biotin
peroxidase complex method. The IHC protocols were described
previously [22]. In short (Figure 1A2), seven TMA sections were
deparaffinized and dehydrated using a graded series of ethanol
solutions. Endogenous peroxidase activity was blocked by 0.3%
hydrogen peroxide for 10 minutes. Antigen retrieval was treated by
microwave treatment in 0.01 M Tris-EDTA buffer (pH 9.0) for 20
minutes. Slides were incubated with primary antibodies of mouse
antihuman polyclonal antibody against HER2 (A-0485, Dako,
Denmark, dilution 1/50), rabbit anti-human monoclonal antibody
against ER (sc-7207, Santa Cruz, USA, dilution 1/100), and PR
(sc-7208, Santa Cruz, USA, dilution 1/100) for 2 hours at 37°C and
then incubated with the corresponding horseradish peroxidase–
conjugated secondary antibody (MaiXin Bio Co., Ltd., Fuzhou,
China, 1:250 dilution) for 30 minutes at 37°C. Negative control was
performed by omitting the primary antibody. Antigen-antibody
reaction was visualized with 3,30′-diaminobenzidine (DAB) (DAKO,
Denmark). After counterstaining with hematoxylin, sections were
dehydrated through ascending alcohols.
The immunostaining results were determined independently by two
expert pathologists (G.F.Y., J.P.Y.) without knowledge of patients'
outcomes. The results of HER2 were scored from 0 to 3+ as the criteria
described [6], and any discernable signals of ER and/or PR positive in the
nucleus were defined as hormone receptor positive [27].
Image Acquisition, Quantification, and Analysis
The digital images of HER2 staining were captured based on 6
photographs for each core of TMAs under Olympus BX51
bright-field microscope equipped with Olympus DP72 RGB camera
(Olympus Optical Co., Ltd., Tokyo, Japan) and CRi Nuance
multispectral imaging systems (Cambridge Research & Instrumen-
tation, Inc., Woburn, MA), respectively, at 100× magnification. The
images of six photographs were integrated to form a panorama image
for each TMAs core. The MS (Figure 1B1, upper panel) and RGB
images (Figure 1B3, upper panel) of each core containing both tumor
nests and stroma were acquired at the unified image acquisition
parameters [15] by two imaging systems. A total of 6 spectral cubes
from 420 to 720 nm in 20-nm increments were acquired by MSI
Figure 1. Flowchart of study design and major technical procedures. (A1) TMAs with 480 cores of 240 BC specimens were constructed.
(A2) Three key molecule biomarkers of BC were stained by routine IHC method, staining HER2 in cell membrane. (B1–B3) The HER2 MS
and RGB images were captured by MSI system, and their unmixing and quantification were obtained by CRi Nuance software. (C1–C3)
HER2 MS and RGB image analysis outputs were analyzed by X-tile software (C1). All patients were divided into two groups (C2) and
analyzed by Kaplan-Meier method (C3).
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obtained including identical 1440 RGB images and 1440 MS images,
and all images were saved in Tagged Image File Format with
consistent resolution for further analysis.
After imaging acquisition, CRi Nuance software V 3.0.0 within
MSI system was used for the unmixing and quantification in HER2
MS and RGB images with standard processing. The spectral
characteristics (curve) for two chromogens (DAB and hematoxylin)
in MS and RGB images were obtained by spectral separation.
Detailed steps were previously described [15,28]. The target images
with different spectra were automatically unmixed into DAB
(Figure 1, B1 and B3, lower panel) and hematoxylin (data not shown)
component images by Nuance software based on spectral library.
Nonspecific background signals were subtracted from each imageindividually. DAB spectral signals of HER2 were automatically
quantified.
The original results produced by CRi Nuance software were total
signal optical density (OD) values for HER2 in one view field. As
each TMA core has six view fields, the final quantitative results output
was HER2 sum, i.e., signal pixels in six fields altogether. To minimize
errors in data interpretation and scoring as well as to improve data
quality, average OD values of all the positive staining of HER2 in
each image were measured. Once the HER2 total signal OD and
average signal OD values in MS and RGB images were calculated, the
X-tile software, which was explored and used to identify optimal cut
point of biomarkers based on the prognosis by scholars at Yale
University in 2004 [29], was applied to automatically identify the
cutoff points of total OD and average OD values in HER2 MS and
524 Multispectral and RGB Imaging in Breast Cancer Liu et al. Translational Oncology Vol. 9, No. 6, 2016RGB images, and all patients were categorized into two groups
according their values (Figure 1, C1–C3).
Statistical Analysis
Statistical analyses were performed with SPSS 19.0 software (SPSS
Institute, Chicago, IL). All numeric values are reported as the
mean ± standard deviation. Correlation test was calculated by
Pearson chi-square. The primary end point, 5-DFS, was calculated
by the Kaplan-Meier method and analyzed by the log-rank test.
Multivariate analysis was performed by the Cox proportional hazards
model. Sensitivity, specificity, positive predictive values (PPVs), and
negative predictive values (NPVs) were calculated. Receiver operating
characteristic (ROC) curve analysis was used to determine the
predictive value of the independent prognosis factors. Two-sided
P b .05 was considered as statistically significant.
Results
IHC Staining Results in TMAs
The main clinicopathologic characteristics of 240 patients in BC
TMAs were presented in Table 1. The median age of patients was
49.5 years (range, 21-89 years), and the average follow-up time was
45.6 months. IHC staining was performed in seven BC TMAs, and
the result of each specimen was obtained for images-based digital
analysis (Figure 2, A–C). HER2 protein was expressed in cellTable 1. Major Clinicopathologic Characteristics of 240 Patients in BC TMAs
Variables Patients (N = 240) %
Age (years)
≤50 149 62.1
N50 91 37.9
Tumor size (cm)
T1 (T ≤ 2) 36 15.0
T2 (2 b T ≤ 5) 162 67.5
T3 (T N 5) 42 17.5
LNs status
Positive 131 54.6
Negative 109 45.4
Histological grade
I 40 16.7
II 141 58.8
III 59 24.6
Clinical stage
I, II 164 68.3
III, IV 76 31.7
Hormone receptor status *
Positive 186 77.5
Negative 54 22.5
HER2 expression
IHC 3+ 51 21.3
IHC 2+ 27 11.3
IHC 0-1+ 162 67.4
HER2 gene status †
Amplification 51 21.3
Nonamplification 189 78.7
Chemotherapy
Yes 199 82.9
No 41 17.1
Radiotherapy
Yes 47 19.6
No 193 80.4
Recurrence
Yes 100 41.7
No 140 58.3
* ER and/or PR positive was defined as hormone receptor positive, which was determined by
immunohistochemical staining according to guideline [27].
† HER2 gene was determined by fluorescent in situ hybridization according to guideline [6].membrane of tumor cells. Among the 240 patients in this study, 162
(67.4%) cases were scored as 0/1+ HER2, 27 (11.3%) cases were scored
as 2+, and 51 (21.3%) cases were scored as 3+ using the visual method.
The corresponding MS and RGB images of HER2 were acquired,
and some representative IHC images were shown in Figure 2, D–I.
Consistent with our previous report [15], HER2 MS images
presented better image qualities compared with RGB images for further
computer analysis.
Quantification of MS Images and RGB Images of HER2
Expression for 5-DFS Prediction
Among the 240 specimens, the HER2 total signal OD values and
the average signal OD values quantified by MS images (i.e., HER2
MS) varied from 0.00 to 2.63 × 105 (median, 1.60 × 104) and from
0.000 to 0.156 (median, 0.013), respectively. Determined by RGB
images (i.e., HER2 RGB), the values were from 0.00 to 2.23 × 105
(median, 1.14 × 104) and from 0.000 to 0.138 (median, 0.009)
accordingly (Tables 2 and 3). The cutoff value of the total signal OD
values in HER2 MS identified by the X-tile software was 4.33 × 104,
and based on this, patients were categorized into high–HER2
expression group (n = 71) and low–HER2 expression group (n = 169).
The 5-DFS of the former was significant shorter than that of the latter
(log-rank test, P b .001; Figure 3A). The cutoff point in HER2 RGB
was 3.89 × 104, and patients with high HER2 expression (n = 62)
had significantly worse 5-DFS than those with low HER2 expression
(n = 178) by determining RGB images (P b .001) (Figure 3B).
Similarly, based on the judgment of X-tile software, the cutoff
point of the average signal OD values in HER2 MS was 0.031, and
patients were categorized into high-HER2 group (n = 73) and
low-HER2 group (n = 167); the cutoff point of HER2 RGB was
0.026, and patients were divided into high-HER2 group (n = 65) and
low-HER2 group (n = 175). Patients with high HER2 expression
had significantly lower 5-DFS than those with low HER2 expression
(P b .001), whether determined by HER2 MS (Figure 4A) or RGB
images (Figure 4B).
The Quantification of HER2 MS Images and RGB Images to
Predict 5-DFS by LN Status
We next evaluated the prediction of HER2MS and RGB images in
patients coupling with different LN status. As shown in Figure 3, by
the determination of total signal OD index, HER2 expression
evaluated by HER2 MS images was inversely correlated with 5-DFS
in LN-positive patients (P b .001, Figure 3C) and LN-negative
patients (P = .007, Figure 3E). For the quantification of HER2 RGB
images, HER2 expression was negatively correlated with 5-DFS in
LN-positive patients (P b .001, Figure 3D) but not in LN-negative
patients (P = .101, Figure 3F). Similar results were also observed in
the average signal OD index (Figure 4, C–F). These findings
indicated that the quantitation of HER2 MS images might be a more
preferable approach in predicting the 5-DFS in BC patients.
Multivariate and Weighted Analysis
To further explore the potential value of HER2 MS images for the
predication of BC prognosis, a multivariate analysis was performed.
The results demonstrated that, by the analysis of the total signal OD
index from HER2 MS images, multivariate analysis could identify
four variables—HER2 status (P b .001), LN status (P = .006),
histological grade (P b .001), and clinical stage (P = .048)—as
independent prognostic factors for 5-DFS. However, only three
Figure 2. Immunohistological findings in BC TMAs. (A–C) Representative examples of HER2 scored as 1+, 2+, and 3+. (D–F) The RGB images
were acquired by traditional RGB imaging system. (G–I) The correspondingMS images were acquired by MSI system. (D and G) Positive HER2
membranestainingwasscoredas1+. (E andH)PositiveHER2membranestainingwasscoredas2+. (F and I) PositiveHER2membranestaining
was scored as 3+. Magnification 40× (A, B, and C) or 100× (D, E, F, G, H, and I); scale bar: 100 μm for all images.
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and histological grade (P b .001) could be identified from HER2
RGB images (Table 4). Similar results were also achieved by the
determination of the average signal OD index (Table 5).
Additionally, the weighted analysis of the impacts of HER2
expressions quantified from HER2 MS images and RGB images on
5-DFS was carried out. As shown in Tables 4 and 5, the hazard ratios
(HRs) of HER2 MS were higher than those of HER2 RGB (HR =
2.454; 95% CI, 1.636-3.681 vs HR = 2.060; 95% CI, 1.361-3.119;
HR = 2.467; 95% CI, 1.650-3.688 vs HR = 2.401; 95% CI,
1.599-3.605) by either total signal OD index or average signal
OD index.
Evaluation of the Prognostic Value of HER2 MS and HER2
RGB Images
ROC curve analysis was implemented to further evaluate the
prognostic performance of these independent factors identified by
multivariate analysis. All factors could predict the recurrence risk wellTable 2. The Total Signal OD Index of HER2 MS and RGB Images, Cutoff Value, and
Classification
Images
Total Signal OD Values
Cutoff
Value
Patients (n)
Median Range
High-HER2
Group
Low-HER2
Group
HER2 MS 1.60 × 104 0.00-2.63 × 105 4.33 × 104 71 169
HER2 RGB 1.14 × 104 0.00-2.23 × 105 3.89 × 104 62 178(P b .05). In predicting recurrence or not, by the comparison of the
total signal OD index, the prognostic value of HER2 MS images
(AUC = 0.649; 95% CI, 0.577-0.722; P b .001) was higher than
HER2 RGB images (AUC = 0.596; 95% CI, 0.522-0.670; P =
.012) and clinical stage (AUC = 0.642; 95% CI, 0.571-0.713;
P b .001) but lower than LN status (AUC = 0.696, 95% CI:
0.628-0.763, P b .001) and histological grade (AUC = 0.748, 95%
CI: 0.686-0.811, P b .001) (Figure 5A). Analogous results were also
revealed in the average signal OD index (Figure 5B).
Evaluation of Prediction Efficiency of HER2 MS and HER2
RGB Images
In addition, the prediction efficiency of HER2 MS and RGB
images in prognostication of BC recurrence was also assessed. As
shown in Table 6, by the comparison of the total signal OD index,
sensitivity, specificity, PPV, and NPV of the prediction of BC
prognosis by HER2 MS images were higher than those of HER2
RGB images (48.0% vs 39.0%, 84.2% vs 83.6%, 69.0% vs 62.9%,able 3. The Average Signal OD Index of HER2 MS and RGB Images, Cutoff Value, and
lassification
ages
Average Signal
OD Values Cutoff
Point
Patients (n)
Median Range High-HER2 Group Low-HER2 Group
ER2 MS 0.013 0.000-0.156 0.031 73 167
ER2 RGB 0.009 0.000-0.138 0.026 65 175T
C
Im
H
H
Figure 3. The relationship between total signal OD index and 5-DFS in BC patients, which was obtained from the analysis of HER2 MS or
HER2 RGB images. HER2 MS (A) and HER2 RGB (B) are negatively related with 5-DFS in all patients. HER2 MS (C) and HER2 RGB (D) are
inversely related with 5-DFS in LN-positive patients. HER2 MS (E) is negatively related with 5-DFS in LN-negative patients, but HER2 RGB
(F) has no statistical significance in LN-negative patients. P value tested by the log-rank test.
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Figure 4. The relationship between average signal OD index and 5-DFS in BC patients, which was obtained from the analysis of HER2MS
or HER2 RGB images. (A–F) Similar results were further observed. P value tested by the log-rank test.
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recurrence was thus obtained for HER2 MS images than HER2 RGB
images (69.6% vs 65.0%). The same trend was also observed by the
determination of the average signal OD index (69.6% vs 64.6%).Discussion
In the present study, we have developed a novel approach to
quantitatively determine the HER2 expression in IHC images
automatically for the better evaluation of the prognosis of BC
Table 4. Multivariate analyses of factors associated with 5-DFS by total signal OD index.
Factors
Analysis from HER2 MS images
Analysis from HER2
RGB images
HR (95% CI) P Value HR (95% CI) P Value
Tumor size 1.131 (0.753-1.698) .552 1.178 (0.789-1.758) .422
LN status 2.260 (1.257-3.061) .006 2.029 (1.129-3.645) .018
Hormone receptor status 0.760 (0.491-1.174) .216 0.706 (0.458-1.089) .115
HER2 status 2.454 (1.636-3.681) b .001 2.060 (1.361-3.119) .001
Histological grade 2.924 (2.000-4.275) b .001 2.143 (2.156-4.580) b .001
Clinical stage 1.572 (1.005-2.460) .048 1.451 (0.926-2.275) .105
5-DFS, 5-year disease-free survival; HR, HR; CI, confidence interval; HER2, human epidermal
growth factor receptor-2; LN, LN; OD, OD.
528 Multispectral and RGB Imaging in Breast Cancer Liu et al. Translational Oncology Vol. 9, No. 6, 2016patients. The quantitation of MS images or conventional RGB images
of HER2 IHC was realized by the use of TMAs of large cohorts of BC
tissue samples. To the best of our knowledge, it is the first time to
quantify the HER2 status by MS images and display their closer
relationshipwith the recurrence-free survival in BCpatients. Additionally,
such quantification by MS images performed better in predicting BC
prognosis than that by RGB images. Coupled with our previous research
about the behavior of MSI in IHC analysis [15], it showed that MSI has
the potential as a standard digital imaging system for both diagnosis and
prediction of BC prognosis in clinical pathology.
With the development of precision medicine, quantitative
pathology with improved imaging technique and image information
acquisition and analysis has attracted more and more attention. In the
aspect of imaging technique, MSI can obtain color spectrum
information at every pixel of a color image rather than specific
color information of the three available channels (red, green, and
blue) by standard RGB imaging [14,30]. MSI collects different
spectral images (from 420 to 720 nm, covering most chromogens)
with accurate spectral content, and a complete image “stack” is
assembled in memory where a spectrum is correlated with every pixel.
This ability significantly improves the efficiency and accuracy of imaging
process, providing a promising way for multiple target imaging under
both bright-field and fluorescence view [17–19,30]. In this study, we
employed RGB imaging and MSI system to get HER2 IHC staining
images in BC TMAs and compared their behaviors. Similar with the
result reported by Boucheron et al. [31], MS images provided better
overall image qualities and more useful information than the standard
RGB images which were vital for further computer analysis.
In the aspect of image information acquisition and analysis, the
CRi Nuance MSI system can allow pathologists to precisely separate
and quantify multiple spatially colocalized chromogens in multicolorTable 5. Multivariate analyses of factors associated with 5-DFS by average signal OD index.
Factors
Analysis from HER2 MS images
Analysis from HER2
RGB images
HR (95% CI) P Value HR (95% CI) P Value
Tumor size 1.150 (0.769-1.722) .496 1.202 (0.809-1.786) .362
LN status 2.086 (1.162-3.743) .014 2.243 (1.251-4.023) .007
Hormone receptor status 0.814 (0.520-1.275) .369 0.811 (0.515-1.277) .365
HER2 status 2.467 (1.650-3.688) b .001 2.401(1.599-3.605) b .001
Histological grade 3.017 (2.065-4.408) b .001 3.293 (2.259-4.801) b .001
Clinical stage 1.585 (1.013-2.480) .044 1.472 (0.940-2.306) .091
5-DFS, 5-year disease-free survival; HR, HR; CI, confidence interval; HER2, human epidermal
growth factor receptor-2; LN, LN; OD, OD.IHC staining by multispectral linear unmixing. It can also realize an
accurate segmentation of different tissue morphologies (e.g., tumor
versus stroma) and cellular and subcellular compartments
[17,32–35]. In our previous study, better segmentation accuracy
and richer color information have been obtained from unmixing MS
images of IHC staining combined MSI with CRi Nuance software
[15]. Xu et al. also reported the potential utility of CRi Nuance MSI
system in quantifying biomarkers and interpreting the spatial and
anatomical distribution of biomarkers of high-order processes [36].
HER2 status, which is closely related to the malignant biologic
behaviors of BC, including aggressiveness and metastasis, has been
used as a critical indicator for the identification of distinct biological
subtypes of BC and prediction of prognosis [9,37]. Quantum dots–
based quantitative spectral analysis of HER2 has helped the
establishment of a new molecular classification system of BC and
the prediction of tumor prognosis [23]. MSI has been reported to
detect some potential prognostic factors [36] and to determine the
pericyte coverage of differentiated vessels inside tumor vasculature as
an independent unfavorable prognostic factor for patients with clear
cell renal cell carcinoma [38,39].
Based on this new approach, the present study systematically
evaluated the clinical value of the quantitation of HER2 MS images
and RGB images coupled with the conventional pathological
prognostic factors using 5-DFS as the primary end point. All BC
patients were divided into two subgroups with different 5-DFS
according to X-title software. The result showed that more patients in
the poor-prognosis group were identified by quantifying HER2 MS
images than those by quantifying RGB images, which were both
inversely correlated with 5-DFS significantly. We further assessed the
prognostic value of HER2 MS and RGB images by LN status, the
most important indicator for evaluating tumor metastasis. Significant
correlation between HER2 RGB and 5-DFS only existed in
LN-positive patients, not in LN-negative patients. Nevertheless,
HER2 MS exhibited statistical significance in both LN-positive and
LN-negative patients (Figures 3 and 4), suggesting the better
predictive ability of HER2 MS on recurrence than HER2 RGB.
Multivariate analysis indicated that HER2MS provided higher HR
than HER2 RGB in predicting 5-DFS (2.454 vs 2.060; 2.467 vs
2.401). Furthermore, HER2 MS had correlation with three major
conventional prognostic factors, including LN status, histological
grade, and clinical stage, but HER2 RGB was only correlated with the
first two factors (Tables 4 and 5). Additionally, ROC curve analysis
showed that HER2 MS had higher prognostic value on recurrence
than HER2 RGB (Figure 5, A and B). Compared with HER2 RGB,
HER2 MS displayed better performance in sensitivity, accuracy,
PPV, and NPV for predicting recurrences (Table 6). Thus, the
quantification of HER2 MS images could be used as a better
approach for prognostic prediction, benefitting from the better
predictive ability among BC subgroups, better performance for
recurrence prediction, and good correlation with the currently
established pathological prognosticators.
We acknowledge some limitations to our study. Firstly, the results
should be evaluated further in a larger multicenter BC patient
population with long-term follow-up. Secondly, only the relationship
between HER2 expression and patient outcome by 5-DFS was
evaluated in this study. It is better to further study the corresponding
relations between HER2 expression and the overall survival because of
the nonlinear relation between DFS and overall survival sometimes.
Thirdly, although image analysis techniques can reduce interobserver
Figure 5. ROC curve analysis on the prognostic value of HER2 MS and HER2 RGB. (A) By the analysis of total signal OD index, AUC of
HER2 MS was greater than HER2 RGB and clinical stage but smaller than LN status and histological grade on recurrence. (B) Similar
results were further realized by the determination of average signal OD index.
Translational Oncology Vol. 9, No. 6, 2016 Liu et al. 529variability, it is impossible to eliminate all subjectivities because the system
was trained manually by a pathologist initially. Finally, the limitation that
every core of TMAswas not able to completely represent thewhole tumor
might lead to the possible sample selection bias.
Conclusions
In this study, we developed an approach for the assessment of HER2
status using quantifying MS images and validated the potential of MS
images on predicting outcome in patients with invasive BC. Our
findings demonstrated that better information on BC prognosis could
be obtained from the quantification of HER2 MS images and the
application of MS images may be better than conventional RGB
images in predicting BC prognosis.
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Century Excellent Talents in Universities (no. NCET-10-0644).Table 6. The prediction efficiency of HER2 MS and HER2 RGB images for BC prognosis.
Items
Analysis from total signal OD index
Analysis from average signal OD
index
HER2 MS
images
HER2 RGB
images
HER2 MS
images
HER2 RGB
images
Sensitivity (%) 48.0 (49/100) 39.0 (39/100) 51.0 (51/100) 40.0 (40/100)
Specificity (%) 84.2 (118/140) 83.6 (117/140) 82.9 (116/140) 82.1 (115/140)
PPV (%) 69.0 (49/71) 62.9 (39/62) 68.0 (51/75) 61.5 (40/65)
NPV (%) 69.8 (118/169) 65.7 (117/178) 70.3 (116/165) 65.7 (115/175)
Accuracy (%) 69.6 (167/240) 65.0 (156/240) 69.6 (167/240) 64.6 (155/240)
BC, BC; HER2, human epidermal growth factor receptor-2; OD, OD; PPV, positive predictive
value; NPV, negative predictive value.References
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